Demexiptiline

Demexiptiline is a tricyclic antidepressant (TCA) that was developed in the 1960s but was never marketed. It is similar in structure and pharmacological effects to other TCAs such as imipramine and desipramine.

Pharmacology[edit | edit source]

Demexiptiline acts primarily as a norepinephrine reuptake inhibitor, which means it increases the amount of norepinephrine in the brain by blocking its reabsorption into nerve cells. This can help to alleviate symptoms of depression.

Chemistry[edit | edit source]

Demexiptiline is a tricyclic compound, meaning it contains three rings of atoms in its chemical structure. It is part of the dibenzazepine class of TCAs, which also includes imipramine and desipramine.

History[edit | edit source]

Demexiptiline was developed in the 1960s as part of a wave of new antidepressant drugs. However, it was never marketed, possibly due to the emergence of newer, safer antidepressants in the following decades.

Side Effects[edit | edit source]

Like other TCAs, demexiptiline can cause a range of side effects, including dry mouth, blurred vision, constipation, urinary retention, and orthostatic hypotension. It can also cause mental effects such as confusion, hallucinations, and changes in mood or behavior.